Abstract:Yan-Yan Hao, 1, 2, &ast Yi-Peng Qiao, 3, &ast Jian-De Cheng 1, 2 1 Department of Respiratory and Critical Care Medicine, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, 030032, Shanxi, People's Republic of China; 2 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, People's Republic of China; 3 Department of Internal Medicine, Qing-Xu County People's Hospital, Taiyuan, 030499, Shanxi, People's Republic of China &astThese authors contributed equally to this work Correspondence: Jian-De Cheng Department of Respiratory and Critical Medicine of Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, 030032, Shanxi, People's Republic of China Tel +86 13834668789 Email Objective: Anlotinib was the standard monotherapy for patients with previously treated small cell lung cancer (SCLC) in recent years. Programmed cell death protein 1 (PD-1) blockade combined with antiangiogenic targeted drugs have proved to play a synergistic action for cancer treatment clinically. Consequently, the present study was to investigate the efficacy and safety of anlotinib combined with PD-1 blockades for patients with previously treated SCLC. Methods: A total of 36 patients with SCLC who were treated with at least one previous systemic chemotherapy regimen participated in this study retrospectively. All the patients were administered with anlotinib plus PD-1 blockades therapy. Clinical activity was assessed according to the change of target lesion by imaging evidence and all the subjects were followed up regularly. Safety profiles were collected and documented during the treatment. Univariate analysis was carried out using Log rank test and multivariate analysis was adjusted by Cox regression analysis. Results: All the 36 patients with previously treated SCLC were able to have their efficacy and safety profile evaluated. The best overall response of the combination regimen showed that complete response was observed in one patient, partial response was noted in 9 patients, stable disease was reported in 19 patients, progressive disease was seen in 7 patients. Therefore, the objective response rate (ORR) of the 36 patients was 27.8% (95% CI: 14.2– 45.2%), disease control rate (DCR) was 80.6% (95% CI: 64.0– 91.8%). Regarding the prognostic data, the median PFS and OS of the 36 patients was 4.6 months (95% CI: 3.13– 6.07) and 9.3 months (95% CI: 3.30– 15.30), respectively. The most common treatment-related adverse reactions were hypertension (52.8%), fatigue (47.2%), diarrhea (38.9%), hand and foot reaction (38.9%) and dermal toxicity (33.3%). Furthermore, multivariate Cox regression analysis for PFS indicated that ECOG performance status was an independent factor to predict PFS. Conclusion: Anlotinib combined with PD-1 blockades regimen preliminarily demonstrated encouraging efficacy and tolerable safety for patients with previously treated SCLC. The conclusion should be validated in prospective clinical trials subsequently. Keywords: small cell lung cancer, anlotinib, PD-1 blockade, efficacy, safety As an aggressive and devastating malignancy, small cell lung cancer (SCLC) is characterized by rapid growth and early metastasis, and accounts for approximately 15% of all diagnosed lung cancers. 1 The estimated prevalence of SCLC was approximately 122,000 new cases and 107,000 new deaths of SCLC in China annually. 2 Almost 70% of the patients with SCLC presented with extensive-stage SCLC (ES-SCLC), which was of dismal prognosis with the 5-year survival rate <3% and median overall survival (OS) of <12 months. 3 To our knowledge, after the failure for first-line regimen of etoposide plus platinum doublet chemotherapy, topotecan remained the recommended second-line treatment in China with the median duration of response only 3 months. 4 Therefore, effective regimens with tolerable safety profile as second-line and above therapy for patients with ES-SCLC are needed currently. It was reported that approximately 80% of SCLC was associated with positive vascular endothelial growth factor (VEGF) expression. 5 Therefore, antiangiogenic targeted drugs demonstrated encouraging efficacy for patients with ES-SCLC recently. 6 Additionally, anlotinib was reported to improve PFS and OS dramatically in a phase II clinical trial (ALTER1202) for patients with SCLC. 7 Consequently, anlotinib had become the standard regimen as third-line mono -Abstract Truncated-

Efficacy and safety of anlotinib combined with PD‐1/PD‐L1 inhibitors as second‐line and subsequent therapy in advanced small‐cell lung cancer

Efficacy and safety of anlotinib plus penpulimab as second-line treatment for small cell lung cancer: A multicenter, open-label, single-arm phase II trial

P1.15-009 Safety and Efficacy of Nab-Paclitaxel Monotherapy As 2nd or Later Line Setting in Pts with Extensive SCLC, a Phase II Single Arm Study (NCT02262897)

The Efficacy and Safety of Anlotinib Combined With PD-1 Antibody for Third-Line or Further-Line Treatment of Patients With Advanced Non-Small-Cell Lung Cancer

Penpulimab plus anlotinib as second-line treatment for the small cell lung cancer after failure of platinum-based systemic chemotherapy.

PD-(L)1 Inhibitors Plus Anlotinib: A Superior Option for Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer.

Combination therapy using low-dose anlotinib and immune checkpoint inhibitors for extensive-stage small cell lung cancer

P1.04-46 PD-1 Inhibitor Plus Chemotherapy As 2nd/subsequent Line Setting Demonstrate Superior Efficacy over PD-1 Inhibitor Alone in Pts of Advanced NSCLC

JCSE01.26 PD-1 Inhibitor Plus Chemotherapy As 2nd/subsequent Line Setting Demonstrate Superior Efficacy over PD-1 Inhibitor Alone in Pts of Advanced NSCLC

Clinical Activity and Safety of Anlotinib Combined with PD-1 Blockades for Patients with Previously Treated Small Cell Lung Cancer

The efficacy and safety profile of anlotinib plus docetaxel as second-line treatment in advanced non-small cell lung cancer.

The Efficiency and Safety of Triple-Drug Combination of Albumin-Bound Paclitaxel, Anlotinib and PD-1/L1 Inhibitors in the 2nd or Above Line of Advanced NSCLC: A Retrospective Cohort Study

Efficacy and Safety Analysis of Anlotinib Combined with PD-1 Inhibitors in Advanced Non-Small Cell Lung Cancer: a Retrospective Cohort Study

Comparative Efficacy and Safety of Multitarget Angiogenesis Inhibitor Combined with Immune Checkpoint Inhibitor and Nivolumab Monotherapy As Second-Line or Beyond for Advanced Lung Adenocarcinoma in Driver-Negative Patients: a Retrospective Comparative Cohort Study.

Anti-PD-1 Therapy Plus Chemotherapy And/or Bevacizumab As Second Line or Later Treatment for Patients with Advanced Non-Small Cell Lung Cancer.

Response to First‐line Treatment Predicts Progression‐free Survival Benefit of Small‐cell Lung Cancer Patients Treated with Anlotinib

Efficacy and safety of anlotinib combined with immune checkpoint inhibitors and platinum-containing chemotherapy for later-line advanced non-small cell lung cancer: a retrospective three-arm real-world study using propensity-score matching

Anlotinib Plus S-1 for Patients with EGFR Mutation-Negative Advanced Squamous Cell Lung Cancer with PS Scores of 2-3 after Progression of Second-Line or Later-Line Treatment

Anlotinib Plus S-1 for Patients with EGFR Mutation-Negative Advanced Squamous Cell Lung Cancer with Poor Performance Status after Second or More -Line Treatment.

The combination therapy of anlotinib and penpulimab for the treatment of small cell lung cancer after platinum-based chemotherapy: Results of a phase II exploratory study.

Clinical efficacy and safety of immune checkpoint inhibitors plus anlotinib as secondline or subsequent therapy in extensive stage small cell lung cancer: a retrospective study